One of the relevant exclusivity periods applies to New Drug Applications (NDA) for approved products containing new chemical entities (NCEs), whereby an ANDA with a paragraph IV certification may not be submitted until four years after the NDA was approved (i.e., the NCE-1 date)
Serious episodes can be associated with extensive muscle cell damage and necrosis, and electrocardiographic (EKG) abnormalities associated with hypokalemia, such as ST and T wave changes, premature ventricular complexes (PVCs), first degree heart block, prolonged QT intervals, and even ventricular fibrillation (337)
Their EMBRAZE Phase 2 trial, combined with tirzepatide, showed 85% of weight loss from fat with no serious adverse events
No peptide is approved by the FDA, EMA, or ANSM for muscle development or performance enhancement